Latest News for: eye disease

Edit

Thyroid Eye Disease (TED) Treatments Market Nears $4.3 Billion by 2032: Emerging Small Molecule Therapies ...

Business Wire 20 Dec 2025
DUBLIN--(BUSINESS WIRE)--The "Thyroid Eye Disease Treatments Market - Global Forecast 2025-2032" ...
Edit

Thyroid Eye Disease (TED) Treatments Market Nears $4.3 Billion by 2032: Emerging Small Molecule Therapies Targeting Orbital Fibroblasts Drive Revenue Growth - ResearchAndMarkets.com

Pharmiweb 20 Dec 2025
DUBLIN--(BUSINESS WIRE)--The "Thyroid Eye Disease Treatments Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering ... Thyroid Eye Disease Treatments Market.
Edit

Thyroid Eye Disease Treatments Industry Analysis, 2025-2032 - Clinical Management is Shifting Toward Individualized Care ...

Nasdaq Globe Newswire 17 Dec 2025
Dublin, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The "Thyroid Eye Disease Treatments Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering ... .
Edit

GenSci and RTW Investments Announce Strategic Partnership on Anti-TSHR Antibody GS-098 (YB-101) for Graves’ Disease and Thyroid Eye Disease, With Global Ex-China Development Being Led by Yarrow Bioscience

Pharmiweb 16 Dec 2025
exclusive global ex-China rights to develop and commercialize GS-098 (YB-101) for Graves’ disease (GD) and thyroid eye disease (TED) ... treatment of Graves’ disease (GD) and thyroid eye disease (TED).
Edit

Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease (Form 8-K) (Aldeyra Therapeutics Inc)

Public Technologies 16 Dec 2025
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease ... New Drug Application (NDA) for the treatment of dry eye disease.
Edit

Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

Pharmiweb 16 Dec 2025
Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease.
Edit

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease (Zai Lab Ltd)

Public Technologies 15 Dec 2025
... evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED) will be discontinued.
Edit

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

Caledonian Record 15 Dec 2025
15 December, 2025, 7.00 AM CET ....
Edit

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease (Form 6-K) (arGEN-X SE)

Public Technologies 15 Dec 2025
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease ... in adults with moderate to severe thyroid eye disease (TED) will be discontinued ... About Thyroid Eye Disease (TED).
Edit

Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease

PR Newswire 15 Dec 2025
Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application to initiate global Phase Ⅲ clinical trials of MHB018A for the treatment of thyroid eye disease (TED).
Edit

University of Auckland team uses umbilical stem cells to treat eye disease

RNZ 11 Dec 2025
Professor Trevor Sherwin and his team have been using the cells to try to treat keratoconus, a disease of the cornea, the thin, clear dome on the front of the eye ... The team was also developing potentially groundbreaking eye drops for the condition.
Edit

Global Diabetic Eye Disease Devices Market Forecast (2025-2032) Featuring Strategic Analysis of Carl Zeiss, Topcon, ...

The Galveston Daily News 09 Dec 2025
DUBLIN--(BUSINESS WIRE)--Dec 9, 2025-- ....
Edit

New $21m research collaboration to develop treatments for eye diseases

Straits Times 03 Dec 2025
The three-year initiative aims to develop two new treatments for glaucoma and myopia ....
Edit

Santen and SERI Collaborate to Advance Disease-Modifying Therapies for Major Eye Diseases (Santen Pharmaceutical Co Ltd)

Public Technologies 03 Dec 2025
) Santen and SERI Collaborate to Advance Disease-Modifying Therapies for Major Eye Diseases ... SERI's mission is to conduct high-impact eye research that prevents blindness, low vision and major eye diseases common to Singaporeans and Asians.
Edit

Anjali Sharma receives over $5 million in NIH funding for brain and eye disease therapies (Washington State University)

Public Technologies 20 Nov 2025
Each five-yearaward supports her lab's ongoing efforts to design nanotherapeutics for hard-to-treat neurological and ocular diseases. [...] ... Attachments Original document Permalink. Disclaimer.

Article Search

tools
×
×
×
×